MedTrace Logo

Measuring the ACT During Non-cardiac Arterial Procedures.

NCT03426293 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-02-06

No results posted yet for this study

Summary

Aim of the MANCO study is to establish for once and for all that monitoring the effect of heparin during NCVI (Non-Cardiac Vascular Interventions) is essential to ensure the individual patient of safe and tailor-made anticoagulation. Not measuring the effect of the administered heparin exposes the patient to unnecessary risks of thrombo-embolic and bleeding complications. First aim of the MANCO study is to prove that the standardized bolus of 5000 IU of heparin, used by 90% of vascular specialists in Europe, results in inadequate anticoagulation in more than 80% of patients. These measurements will be performed using the Hemostasis Management System by Medtronic.

Conditions

  • Arterial Disease
  • Surgery
  • PTA
  • Peripheral Arterial Disease

Interventions

OTHER

Measuring the ACT to determine effect of heparin

Measuring the ACT to determine effect of heparin during non-cardiac arterial procedures

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • Dijklander Ziekenhuis

    lead OTHER

Principal Investigators

  • Arno M Wiersema, MD, PhD · Dijklander Ziekenhuis

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-21
Primary Completion
2024-01-31
Completion
2024-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03426293 on ClinicalTrials.gov